The company is committed to creating treatments that look beyond traditional symptom management, instead targeting underlying biological damage. As biotech continues to expand the possibilities for targeted therapies, Gain Therapeutics’ approach offers a glimpse into what the next generation of disease intervention might look like for those affected by Parkinson’s and similar conditions.

‍